Related Experiment Videos

Targeted deletion of Nrf2 reduces urethane-induced lung tumor development in mice

Alison K Bauer1, Hye-Youn Cho, Laura Miller-Degraff

  • 1Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States of America. alison.bauer@ucdenver.edu

Plos One
|November 1, 2011
PubMed

Insights

Nuclear factor erythroid 2-related factor 2 (Nrf2) deficiency suppresses lung tumorigenesis by reducing cell survival and tumor expansion. This suggests Nrf2 promotes cancer development and chemoresistance.

Area of Science:

  • Molecular Biology
  • Toxicology
  • Oncology

Background:

  • Nuclear factor erythroid 2-related factor 2 (Nrf2) is crucial for cellular redox and defense.
  • However, sustained Nrf2 activation in lung cancer drives malignancy and chemoresistance.

Purpose of the Study:

  • To investigate the role of Nrf2 in chemically-induced lung neoplasia.
  • To determine if Nrf2 possesses cell survival properties and if its absence suppresses tumor development.

Main Methods:

  • Mice lacking Nrf2 (Nrf2-/-) and wild-type (Nrf2+/+) mice were treated with urethane.
  • Lung injury, inflammation, and tumor formation were assessed via bronchoalveolar lavage, histopathology, and gross analysis.
  • Transcriptomic analysis identified Nrf2-dependent gene expression changes.

Main Results:

  • Nrf2-/- mice exhibited increased lung hyperpermeability, cell death, and inflammation post-urethane exposure.
  • Fewer lung adenomas formed in Nrf2-/- mice compared to Nrf2+/+ mice at 12 and 22 weeks.
  • Nrf2 influenced genes involved in cell signaling, glutathione metabolism, oxidative stress, immune response, cell cycle, and carcinogenesis.

Conclusions:

  • Nrf2 deficiency significantly reduces susceptibility to urethane-induced lung tumorigenesis in mice.
  • Nrf2 appears to promote cancer cell survival and expansion, contributing to malignancy.
  • These findings support the concept of Nrf2 over-activation as an adaptive cancer response promoting malignancy and drug resistance.